Recombinant Human TPO

Phase 1Small molecule

PPeking University People's Hospital

Recombinant Human TPO is one of 27 small molecule programs targeting Surgery. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SurgeryRecruiting

SurgeryPhase 1

Recruiting

Competition

Competitive Landscape

33 competitors in Surgery

#DrugCompanyPhaseTrials

Journavx

Vertex Pharmaceuticals

Approved

1 2

Alfenta

Jazz Pharmaceuticals

Approved

1 3

Neo-Synephrine

EExela Pharma Sciences, LLC.

Approved

3 4

Nubain

AAultman Health Foundation

Approved

2 5

Levophed

GGeneral Hospital of Ningxia Medical University

Approved

2 6

Desferal

Jazz Pharmaceuticals

Phase 3

1 7

Cardene

Sun Pharmaceutical Industries, Inc.

Phase 2

2 8

Tukysa

Pfizer

Phase 2

1 9

Senna

MMedtronic - MITG

Phase 3

1 10

Inlyta

PPrism Pharmaceuticals

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

Surgery

NCT06725082

Clinical

Trials by Indication[1]

Surgery1 trial

Impact of Recombinant Humanized Type III Collagen on the Immediate and Long-term Effects of Breast Tumor Surgery

Recruiting·PPeking University People's Hospital·Phase 1·NCT06725082·30 enrolled

Immune Thrombocytopenia1 trial

The Combination of Prednisone and Recombinant Human Thrombopoietin for Treatment of Immune Thrombocytopenia in Pregnancy

Unknown status·PPeking University People's Hospital·Phase 2·NCT05333744·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Recombinant Human TPO. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Recombinant Human TPO compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Recombinant Human TPO. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peking University People's Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: PPeking University People's Hospital

Recombinant Human TPO

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Surgery1 trial

Immune Thrombocytopenia1 trial

References

Drug Info

Quick Facts

Related News